Phenominer Database Results (488 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
F344/NHsd percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 30.0 % in vivo visual assessment 3024000.0 0 70149 1299
DA/Bkl post-insult time to onset of experimental arthritis type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 105 15.0 d 0.2 2.0 in vivo visual assessment 0.0 immunized 10 days variable 68143 850
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 70.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68198 829
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 71.4 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68219 829
DA.ACI-(D10Rat2-D10Rat29)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 3 14.7 d 1.44 2.5 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68719 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 75.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68735 829
DA/Bkl percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 10 50.0 % in vivo visual assessment 0.0 0 69551 1158
DA/Bkl percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 12 83.3 % in vivo visual assessment 0.0 0 69552 1158
DA/Bkl post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 70 days-105 days 12 15.8 d 3.3 11.43 in vivo visual assessment 0.0 0 69553 1158
WF.WKY-(D5Uwm76-D5Uwm92)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 58 4.8 null 0.4 3.05 in vivo visual assessment 0.0 0 70304 653
WF.WKY-(D5Uwm78-D5Uwm84)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 41 8.1 null 0.6 3.84 in vivo visual assessment 0.0 0 70307 653
WF.WKY-(D5Uwm87-D5Uwm92)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 56 6.3 null 0.4 2.99 in vivo visual assessment 0.0 0 70309 653
BBDR/Rhw percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 11 100.0 % in vivo visual assessment 0.0 0 69921 1241
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 100.0 % in vivo visual assessment 0.0 0 70192 1301
DA/Ztm experimental autoimmune encephalomyelitis duration spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 9.0 d 2.67 8.0 in vivo visual assessment 0.0 0 69953 1258
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 12.2 d 0.18 0.4 in vivo visual assessment 0.0 0 70196 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 33.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69385 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69409 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 31.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69429 892
DA.ACI-(D10Rat12-D10Rat144) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 14.4 d 2.8 7.41 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68221 829
BN-Lx/Cub litter size control condition Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33. single birth offspring quantity male 90 days 9 4.5 null 0.63 1.9 in vivo visual assessment 0.0 0 69024 1076
E3 post-insult time to onset of experimental arthritis pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 0.0 d in vivo visual assessment 1.296E7 0 70132 1282
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 17.0 d 0.9 3.0 in vivo visual assessment 1.296E7 0 70133 1282
LEW.1F subjects with ankylosis to total subjects with arthritis ratio pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 0.0 % in vivo visual assessment tail 1.296E7 0 70135 1282
LEW.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 14 14.0 % in vivo visual assessment 0.0 0 69628 1161
LEW.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 9 11.0 % in vivo visual assessment 0.0 0 69629 1161
LEW.1AV1 subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 2 0.0 % in vivo visual assessment 0.0 0 69634 1161
LEW.1AV1 post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 1 median 22.0 d in vivo visual assessment 0.0 0 69641 1161
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 17 29.0 % in vivo visual assessment 0.0 0 69642 1161
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 17 71.0 % in vivo visual assessment 0.0 0 69645 1161
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 26 69.0 % in vivo visual assessment 0.0 0 69646 1161
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 17 median 24.0 d in vivo visual assessment 0.0 0 69651 1161
DXE2/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 24 33.0 % in vivo visual assessment 0.0 0 69666 1159
LEW.1N post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 21.0 d 2.11 7.0 in vivo visual assessment 0.0 0 69670 1159
E3/ZtmRhd post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 23 38.0 d 1.25 6.0 in vivo visual assessment 0.0 0 69672 1159
DXE2/Ztm percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 24 30.0 % in vivo visual assessment 0.0 0 69682 1159
DXE3/Ztm percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 0.0 % in vivo visual assessment 0.0 0 69683 1159
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 13 69.0 % in vivo visual assessment 0.0 0 68123 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 21 11.7 d 2.23 10.2 in vivo visual assessment 0.0 0 69490 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 13 22.5 d 3.58 12.9 in vivo visual assessment 0.0 0 69492 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 20.0 d 8.5 in vivo visual assessment 0.0 0 69501 837
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 53.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67876 829
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 13 10.1 d 2.63 9.5 in vivo visual assessment 0.0 0 69377 837
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 24 100.0 % in vivo visual assessment 0.0 0 69719 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69720 1162
IER/Ihr percentage of study population developing cataract during a period of time control condition Yokoyama M, et al., Mamm Genome 2001 Mar;12(3):207-11. lens clarity trait male 0 days-120 days 73 100.0 % in vivo visual assessment 0.0 0 69907 1239
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69721 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 13.1 d 1.1 4.4 in vivo visual assessment 0.0 0 69786 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 16.9 d 0.6 1.9 in vivo visual assessment 0.0 0 69789 1162
E3/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 10 0.0 % in vivo visual assessment 2419200.0 0 69839 1164
E3/ZtmRhd arthritic paw count pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 10 0.0 null in vivo visual assessment 2419200.0 0 69841 1164
HanTac:WH litter size bisphenol A (0.025 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 21 11.7 null 0.5 2.3 in vivo visual assessment 0.0 0 96598 1559
HanTac:WH areola mammae/nipple number vehicle control condition (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. nipple quantity male 14 days 17 0.1 null 0.05 0.2 in vivo visual assessment 0.0 0 96627 1559
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 43.0 % in vivo visual assessment 0.0 0 84881 1301
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 14.4 d 0.73 2.2 in vivo visual assessment 0.0 0 84915 1301
HanTac:WH number of fetuses lost perinatally to litter size ratio bisphenol A (5 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. stillborn offspring quantity female 0 days 18 6.8 % 1.27 5.4 in vivo visual assessment 0.0 0 96595 1559
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 100.0 % in vivo visual assessment 0.0 0 84465 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 14.6 d 1.39 6.8 in vivo visual assessment 0.0 0 84467 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time 0.9% sodium chloride solution (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 10 0.0 % in vivo visual assessment 0.0 0 97070 1158
BDIX percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait male 200 days 57 55.0 % 0.89 6.75 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98142 2018
BDIX.BDIV-D6Rat132-D6Mgh3/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait both 200 days 86 25.0 % 0.46 4.25 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98150 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 200 days 56 75.0 % 0.8 6.0 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98168 2018
SD-Cftrem2Apb litter size control condition McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. fertility trait female 0 days 0 11.7 null in vivo visual assessment 0.0 0 SD-Cftrem2Apb (RS:0005135), 7 het ko trios 26 litters 110765 3184
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 5.0 d 0.0 0.0 in vivo visual assessment 0.0 0 110782 3186
SD-Cftrem2Apb ratio of survivors of meconium ileus to total study population during a period of time controlled ColonLYTELY content drinking water (4.5 %) (for 60 days) McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. total life span not specified 60 days 0 34.0 % 0.0 in vivo visual assessment 0.0 0 ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879) 111462 3184
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 18 39.0 % in vivo visual assessment 0.0 100 days two treatment fluorouracil 5-FU 111147 3196
ISIAH litter size control condition Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. single birth offspring quantity female 98 days-112 days 5 8.6 null 2.1 4.7 in vivo visual assessment 0.0 0 110669 3182
WAG/Nov litter size control condition Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21. single birth offspring quantity female 98 days-112 days 5 7.6 null 0.7 1.57 in vivo visual assessment 0.0 0 110670 3182
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110797 3186
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 5 8.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110800 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 0.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110790 3186
LOU/M experimental autoimmune encephalomyelitis duration rat anti-Hu-MBP T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 9 6.0 d 1.0 3.0 in vivo visual assessment 0.0 0 110784 3186
WF.WKY-(D7Rat171-D7Rat128)/1Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 17 3.5 null 0.61 2.5 in vivo visual assessment 0 DMBA oral gavage 105 days 66060 654
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 100.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69397 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 86.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69415 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 16.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69422 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 2.7 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69428 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 28.9 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69433 892
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 45.0 % in vivo visual assessment 0.0 0 84878 1301
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 33.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days 69379 892
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 21 76.0 % in vivo visual assessment 0.0 0 visual observation 69488 837
DA.PVG.1AV1-(D4Rat155-D4Rat84) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 17.6 d 0.8 2.99 in vivo visual assessment 0.0 0 69779 1162
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 8 18.0 d 1.0 2.83 in vivo visual assessment 0.0 0 69818 1163
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 13 median 22.0 d in vivo visual assessment 0.0 0 69650 1161
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 26 median 22.0 d in vivo visual assessment 0.0 0 69652 1161
HanTac:WH number of male offspring to litter size ratio bisphenol A (0.025 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 21 49.8 % 3.21 14.7 in vivo visual assessment 0.0 0 96608 1559
HanTac:WH number of male offspring to litter size ratio bisphenol A (50 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 18 56.2 % 2.45 10.4 in vivo visual assessment 0.0 0 96611 1559
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 76.9 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67859 829
DA.ACI-(D10Rat219-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 11.5 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68215 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 30.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68718 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68732 829
WF.WKY-(D5Uwm67-D5Uwm78)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 32 8.6 null 0.8 4.53 in vivo visual assessment 0.0 0 70299 653
WF.WKY-(D5Uwm78-D5Uwm84)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 29 8.8 null 0.7 3.77 in vivo visual assessment 0.0 0 70305 653
DA/Ztm percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 56.0 % in vivo visual assessment 0.0 0 69951 1258
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 96.3 % in vivo visual assessment 0.0 0 70188 1301
PVG.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 29 0.0 % in vivo visual assessment 0.0 0 70190 1301
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 13 15.4 % in vivo visual assessment 0.0 0 70193 1301
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 18 89.0 % in vivo visual assessment 0.0 0 84892 1301
LEW/SsNHsd percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait not specified 77 days-105 days 6 0.0 % in vivo visual assessment 0.0 0 97068 1158
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 16 20.2 d 2.98 11.9 in vivo visual assessment 0.0 0 84910 1301
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 14.9 d 1.03 3.4 in vivo visual assessment 0.0 0 84916 1301
HanTac:WH number of fetuses lost perinatally to litter size ratio bisphenol A (50 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. stillborn offspring quantity female 0 days 18 17.9 % 6.25 26.5 in vivo visual assessment 0.0 0 96596 1559
WF.COP-(D7Rat39-D7Uwm12)/2Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 16 2.0 null 0.38 1.5 in vivo visual assessment 0 DMBA oral gavage 105 days 66066 654
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 15 100.0 % in vivo visual assessment 3024000.0 0 70146 1299
F344/NHsd percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 10 20.0 % in vivo visual assessment 3024000.0 0 70148 1299
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 4 8.7 d 2.8 5.6 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68212 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 30.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68213 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68216 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68722 839
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 1 3.0 d 0.0 0.0 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68730 829
DA/Bkl post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 70 days-105 days 10 14.4 d 1.3 4.11 in vivo visual assessment 0.0 0 69554 1158
BN percentage of study population developing experimental autoimmune encephalomyelitis during a period of time central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) Roth MP, et al., J Immunol 1999 Feb 15;162(4):1917-22. central nervous system integrity trait not specified 70 days-122 days 9 0.0 % in vivo visual assessment 0.0 0 69967 1278
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70 days-145 days 36 72.0 % in vivo visual assessment 0.0 0 69969 1279
WF.WKY-(D5Uwm76-D5Uwm61)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 40 4.2 null 0.4 2.53 in vivo visual assessment 0.0 0 70297 653
WF.WKY-(D5Uwm85-D5Uwm92)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 51 3.9 null 0.3 2.14 in vivo visual assessment 0.0 0 70310 653
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 0 69923 1241
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 78.0 % in vivo visual assessment 0.0 0 69949 1258
DA/Ztm percentage of study population developing acute experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 22.0 % in vivo visual assessment 0.0 0 69950 1258
DA.PVG-(D4Rat141-D4Mgh11) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 30 10.0 % in vivo visual assessment 0.0 0 70191 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 100.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68132 839
DA/Ztm subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 50.0 % in vivo visual assessment 0.0 0 69631 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 11 18.0 % in vivo visual assessment 0.0 0 69632 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 11 median 18.0 d in vivo visual assessment 0.0 0 69639 1161
LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 13 77.0 % in vivo visual assessment 0.0 0 69644 1161
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 median 22.0 d in vivo visual assessment 0.0 0 69649 1161
DXE3/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 10.0 % in vivo visual assessment 0.0 0 69667 1159
DXE2/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 24 72.0 d 6.94 34.0 in vivo visual assessment 0.0 0 69674 1159
DXE3/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 32.0 d 3.35 15.0 in vivo visual assessment 0.0 0 69675 1159
E3/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 23 0.0 % in vivo visual assessment 0.0 0 69680 1159
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 19.6 d 2.22 10.4 in vivo visual assessment 0.0 0 69493 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 22.5 d 12.9 in vivo visual assessment 0.0 0 69500 837
DA/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 17 100.0 % in vivo visual assessment 0.0 0 69716 1162
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 17.4 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 38days 69407 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 17.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69420 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 13.3 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69423 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 17 9.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69425 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 7.5 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69437 892
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 30.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68228 829
DA.ACI-(D10Rat219-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 7.4 d 1.2 4.33 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68230 829
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 22.6 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69396 892
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69723 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69724 1162
DA/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 17 12.1 d 0.3 1.24 in vivo visual assessment 0.0 0 69784 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 14.2 d 0.4 1.26 in vivo visual assessment 0.0 0 69790 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 33.0 % in vivo visual assessment 0.0 0 69710 1162
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 100.0 % in vivo visual assessment 0.0 0 69712 1162
HanTac:WH gestation period length bisphenol A (0.025 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. gestation period duration female 0 days 21 22.9 d 0.08 0.36 in vivo visual assessment 0.0 0 96584 1559
HanTac:WH number of perinatal live-born offspring deaths to litter size ratio bisphenol A (0.25 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. total life span female 0 days 17 2.5 % 1.19 4.9 in vivo visual assessment 0.0 0 96604 1559
HanTac:WH areola mammae/nipple number bisphenol A (0.25 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. nipple quantity male 14 days 17 0.2 null 0.05 0.2 in vivo visual assessment 0.0 0 96629 1559
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 64.0 % in vivo visual assessment 0.0 0 84886 1301
HanTac:WH number of male offspring to litter size ratio bisphenol A (0.25 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 17 45.1 % 5.46 22.5 in vivo visual assessment 0.0 0 96609 1559
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 91.7 % in vivo visual assessment 0.0 0 84466 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 14.6 d 0.63 3.1 in vivo visual assessment 0.0 0 84468 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 100.0 % in vivo visual assessment 0.0 0 84470 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 14.9 d 1.52 5.9 in vivo visual assessment 0.0 0 84471 1301
BDIX.BDIV-D6Mit1-D6Mgh2/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait both 200 days 100 24.0 % 0.45 4.5 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98147 2018
BDIX.BDIV-D6Mit1-D6Mgh2/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait male 200 days 51 38.0 % 1.05 7.5 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98145 2018
BDIV percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait both 200 days 112 0.0 % in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis 98157 2018
BDIX.BDIV-D6Mit1-D6Mgh2/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 200 days 49 90.0 % 0.64 4.5 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98162 2018
BDIX.BDIV-D6Rat132-D6Mgh3/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 200 days 39 78.0 % 1.12 7.0 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98164 2018
BDIX.BDIV-D6Rat132-D6Mgh3/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 200 days 47 74.0 % 0.69 4.75 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98165 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 200 days 62 74.0 % 0.73 5.75 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98169 2018
BDIV ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 200 days 49 100.0 % in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98172 2018
SD-Cftrem1Apb litter size control condition McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. fertility trait female 0 days 3 9.8 null in vivo visual assessment 0.0 0 3 het p508 x 3 homo p508 16 litters 110764 3184
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time rat anti-Hu-MBP T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 9 100.0 % in vivo visual assessment 0.0 0 110780 3186
SD-Cftrem2Apb ratio of survivors of meconium ileus to total study population during a period of time controlled ColonLYTELY content drinking water (4.5 %) (for 7 days) McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. total life span not specified 7 days 0 60.0 % 0.0 in vivo visual assessment 0.0 0 ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879) 111460 3184
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 18 44.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + interleukin-2 111148 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 18 0.0 % in vivo visual assessment 0.0 150 days two treatment fluorouracil 5-FU 111151 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 21 9.5 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111153 3196
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110799 3186
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110801 3186
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis rat anti-Hu-MBP T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 9 6.0 d 1.0 3.0 in vivo visual assessment 0.0 0 110783 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110794 3186
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 94.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days 69390 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 18.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 31days 69395 892
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 17.2 d 1.63 5.4 in vivo visual assessment 0.0 0 84925 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 14.1 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69410 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 18.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69417 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 11.5 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69419 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 9 28.4 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69431 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 50.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69435 892
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 100.0 % in vivo visual assessment 1.296E7 0 70128 1282
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 10.1 d 9.5 in vivo visual assessment 0.0 0 69502 837
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 85.7 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67875 829
DA.PVG.1AV1-(D4Rat155-D4Rat84) post-insult time to onset of experimental arthritis Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 13.6 d 0.4 1.5 in vivo visual assessment 0.0 0 69776 1162
DA/Ztm post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 14.0 d 0.7 2.1 in vivo visual assessment 0.0 0 69788 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 15.5 d 0.8 2.53 in vivo visual assessment 0.0 0 69793 1162
LEW/Han percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 82.0 % in vivo visual assessment 0.0 0 69676 1159
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 15.2 d 0.2 0.6 in vivo visual assessment 0.0 0 69782 1162
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 13.0 d 1.8 5.09 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68197 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67852 829
DA.PVG-(D4Rat141-D4Mgh11) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 30 31.7 d 1.86 10.2 in vivo visual assessment 0.0 0 70195 1301
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 12.4 d 0.49 1.3 in vivo visual assessment 0.0 0 70200 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 37 14.0 d 0.0 0.0 in vivo visual assessment 0.0 0 70202 1301
DA/ZtmRhd post-insult time to onset of experimental arthritis pristane (150 ul) (for 56 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 30 14.0 d 0.37 2.0 in vivo visual assessment 4838400.0 0 69593 1160
DA/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) (for 120 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 30 87.0 % in vivo visual assessment 1.0368E7 0 69595 1160
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 16.2 d 0.92 2.6 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68707 839
BBDR/Rhw percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 13 100.0 % in vivo visual assessment 0.0 0 69922 1241
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 55.0 % in vivo visual assessment 0.0 0 84889 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time 0.9% sodium chloride solution (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 12 0.0 % in vivo visual assessment 0.0 0 97071 1158
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 10 12.6 d 0.32 1.0 in vivo visual assessment 0.0 0 84918 1301
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 12.7 d 0.45 1.2 in vivo visual assessment 0.0 0 84920 1301
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 22.0 % in vivo visual assessment 0.0 0 84876 1301
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 13 16.0 d 0.0 0.0 in vivo visual assessment 0.0 0 84903 1301
WF.WKY-(D7Rat51-D7Rat128)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 23 8.0 null 0.85 4.1 in vivo visual assessment 0 DMBA oral gavage 105 days 66062 654
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 33.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67848 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 3.5 d 1.7 5.89 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68194 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 16.4 d 2.6 7.35 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68200 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68204 829
DXE3/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) (for 110 days) Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32. joint integrity trait both 0 days 1 43.0 d in vivo visual assessment 9504000.0 0 70145 1298
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 14.0 d 1.06 5.5 in vivo visual assessment 0.0 0 70194 1301
E3/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) (for 56 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 25 0.0 % in vivo visual assessment 4838400.0 0 69592 1160
DA.PVG.1AV1-(D4Rat155-Spr) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 13.7 d 0.43 1.5 in vivo visual assessment 0.0 0 70198 1301
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 7 14.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68726 839
LEW percentage of study population developing experimental autoimmune encephalomyelitis during a period of time central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) Roth MP, et al., J Immunol 1999 Feb 15;162(4):1917-22. central nervous system integrity trait not specified 70 days-122 days 9 100.0 % in vivo visual assessment 0.0 0 69968 1278
ACI/SegHsd percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70 days-145 days 21 5.0 % in vivo visual assessment 0.0 0 69970 1279
WF.WKY-(D5Uwm76-D5Got18)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 27 3.5 null 0.4 2.08 in vivo visual assessment 0.0 0 70300 653
WF.WKY-(D5Uwm67-D5Uwm81)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 26 8.3 null 0.7 3.57 in vivo visual assessment 0.0 0 70303 653
WF.WKY-(D5Uwm78-D5Uwm93)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 27 5.0 null 0.5 2.6 in vivo visual assessment 0.0 0 70306 653
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 91.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68135 839
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 105 100.0 % in vivo visual assessment 0.0 immunized 10 days variable 69959 850
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 64.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days 69378 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 4.9 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69389 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 14.3 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31 days days 69392 892
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 1 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68729 839
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 23.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69411 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 18.7 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69418 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 7.8 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69434 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 14 18.5 d 1.6 5.99 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68224 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 8.6 d 1.5 4.74 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68227 829
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 100.0 % in vivo visual assessment 1.296E7 0 70129 1282
LEW.1F arthritic paw count pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 3.4 null 0.21 0.7 in vivo visual assessment tail 1.296E7 0 70138 1282
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 21 100.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 DA.PVG.1AV1-(D4Got128-D4Got136) for strain 68130 838
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 100.0 % in vivo visual assessment 0.0 0 69625 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 15 73.0 % in vivo visual assessment 0.0 0 69626 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 11 36.0 % in vivo visual assessment 0.0 0 69633 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 11 median 18.0 d in vivo visual assessment 0.0 0 69638 1161
LEW.1AV1 post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 2 median 18.0 d in vivo visual assessment 0.0 0 69640 1161
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 28 median 24.0 d in vivo visual assessment 0.0 0 69653 1161
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 90.0 % in vivo visual assessment 0.0 0 69725 1162
DA.PVG.1AV1-(D4Rat155-Spr) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 14.3 d 0.3 1.12 in vivo visual assessment 0.0 0 69780 1162
DA/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 14.2 d 1.1 3.48 in vivo visual assessment 0.0 0 69792 1162
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 104 100.0 % in vivo visual assessment 2419200.0 0 69838 1164
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 100.0 % in vivo visual assessment 0.0 0 69703 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 0.0 % in vivo visual assessment 0.0 0 69704 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 88.0 % in vivo visual assessment 0.0 0 69706 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 36.0 % in vivo visual assessment 0.0 0 69708 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 71.0 % in vivo visual assessment 0.0 0 69711 1162
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 13 100.0 % in vivo visual assessment 0.0 0 69715 1162
HanTac:WH number of male offspring to litter size ratio vehicle control condition (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 18 50.5 % 4.36 18.5 in vivo visual assessment 0.0 0 (number of males to litter size) ratio) 96607 1559
HanTac:WH areola mammae/nipple number bisphenol A (50 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. nipple quantity male 14 days 17 0.4 null 0.15 0.6 in vivo visual assessment 0.0 0 96631 1559
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 8 14.4 d 1.73 4.9 in vivo visual assessment 0.0 0 84923 1301
DA.PVG.1AV1-(D4Got126-D4Got136) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 19.0 d 1.18 4.4 in vivo visual assessment 0.0 0 84924 1301
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 100.0 % in vivo visual assessment 0.0 0 84877 1301
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 13.0 d 0.38 1.3 in vivo visual assessment 0.0 0 84919 1301
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 15.4 d 0.66 2.3 in vivo visual assessment 0.0 0 84921 1301
BDIX.BDIV-D6Rat132-D6Mgh3/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait female 200 days 47 26.0 % 0.69 4.75 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98149 2018
BDIX.BDIV-D6Rat132-D6Rat229/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait both 200 days 24 19.0 % 1.74 8.5 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98151 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait female 200 days 62 26.0 % 0.73 5.75 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98153 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait both 200 days 118 25.0 % 0.37 4.0 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98154 2018
BDIV percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait female 200 days 49 0.0 % in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis 98156 2018
BDIX ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait female 200 days 52 59.0 % 1.07 7.75 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98159 2018
BDIX.BDIV-D6Mit1-D6Mgh2/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 200 days 51 62.0 % 1.05 7.5 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98161 2018
BDIX.BDIV-D6Mit1-D6Mgh2/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 200 days 100 76.0 % 0.45 4.5 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98163 2018
BDIX.BDIV-D6Rat132-D6Mgh3/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 200 days 86 75.0 % 0.46 4.25 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98166 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 200 days 118 75.0 % 0.37 4.0 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98170 2018
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 16 19.0 % 0.0 0.0 in vivo visual assessment 0.0 100 days two treatment regimen saline control group 111146 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 21 81.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111149 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 18 0.0 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + interleukin-2 111152 3196
Sah:SD litter size control condition McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. fertility trait female 0 days 0 10.2 null in vivo visual assessment 0.0 0 Sah:SD (RS:0005133) 111383 3184
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110798 3186
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 8.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110803 3186
SD-Cftrem1Apb ratio of survivors of meconium ileus to total study population during a period of time control condition McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. total life span not specified 60 days 0 66.0 % 0.0 in vivo visual assessment 0.0 0 ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879) 111461 3184
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 100.0 % in vivo visual assessment 0.0 0 110781 3186
WF.WKY-(D7Rat171-D7Rat45)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 28 3.4 null 0.4 2.1 in vivo visual assessment 0 DMBA oral gavage 105 days 66064 654
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 11.8 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69399 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 17.6 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69408 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69412 892
LEW/Han post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 23.0 d 3.02 10.0 in vivo visual assessment 0.0 0 69668 1159
DXE1/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 31.0 d 4.7 21.0 in vivo visual assessment 0.0 0 69673 1159
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 6.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69386 892
DA/Ztm post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 13.0 d 0.4 1.55 in vivo visual assessment 0.0 0 69773 1162
PVG.1AV1 post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 18 38.0 d 1.2 5.09 in vivo visual assessment 0.0 0 69785 1162
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 80.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67849 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 62.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67855 829
DA.F344-(D10Rat204-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70155 1299
HanTac:WH areola mammae/nipple number bisphenol A (5 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. nipple quantity male 14 days 17 0.3 null 0.1 0.4 in vivo visual assessment 0.0 0 96630 1559
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 14 13.4 d 2.2 8.23 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68209 829
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 25.0 % in vivo visual assessment 0.0 0 70197 1301
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 6 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68713 839
DA.ACI-(D10Rat2-D10Rat29)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 1 23.0 d in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68727 839
WF.WKY-(D5Uwm82-D5Uwm92)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 18 2.6 null 0.6 2.55 in vivo visual assessment 0.0 0 70311 653
WF/NHsd mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 46 7.9 null 0.5 3.39 in vivo visual assessment 0.0 0 70314 653
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 75.0 % in vivo visual assessment 0.0 0 84882 1301
SD-Cftrem1Apb ratio of survivors of meconium ileus to total study population during a period of time control condition McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18. total life span not specified 7 days 0 84.0 % 0.0 in vivo visual assessment 0.0 0 ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879) 111459 3184
BDIX.BDIV-D6Rat132-D6Mgh3/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait male 200 days 39 22.0 % 1.12 7.0 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98148 2018
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 0.0 % in vivo visual assessment 0.0 0 84874 1301
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 100.0 % in vivo visual assessment 0.0 0 84880 1301
WF.WKY-(D7Rat171-D7Rat128)/2Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 32 3.9 null 0.46 2.6 in vivo visual assessment 0 DMBA oral gavage 105 days 66061 654
WF.COP-(D7Rat39-D7Uwm12)/1Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 16 2.4 null 0.4 1.6 in vivo visual assessment 0 DMBA oral gavage 105 days 66065 654
N:HS percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (50-120 ug) and Freund's complete adjuvant (100 ul) Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 central nervous system integrity trait both 132 days-177 days 217 41.0 % in vivo visual assessment 0.0 0 66040 114
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67853 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67856 829
DA.F344-(D10Arb20-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70153 1299
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68207 829
DA.ACI-(D10Rat10-D10Rat142) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 13.5 d 3.1 7.59 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68218 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68717 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 14.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68734 829
WF.WKY-(D5Uwm67-D5Uwm98)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 35 3.2 null 0.4 2.37 in vivo visual assessment 0.0 0 70296 653
WF.WKY-(D5Uwm76-D5Uwm98)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 26 3.8 null 0.4 2.04 in vivo visual assessment 0.0 0 70298 653
WF.WKY-(D5Uwm82-D5Uwm91)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 58 3.4 null 0.3 2.28 in vivo visual assessment 0.0 0 70312 653
E3/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) (for 120 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 25 0.0 % in vivo visual assessment 1.0368E7 0 69966 1160
E3/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait female 56 days-103 days 12 0.0 % in vivo visual assessment 0.0 0 69955 1258
BN/SsN percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 immunized 10 days variable 69961 850
DA/Ztm post-insult time to onset of experimental autoimmune encephalomyelitis spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 13.0 d 2.0 6.0 in vivo visual assessment 0.0 0 69952 1258
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 7 0.0 % in vivo visual assessment 0.0 0 69924 1241
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 15.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 31days days 69398 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 91.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69406 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 22.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69414 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 11.2 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69421 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 6.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69430 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 28.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69436 892
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 38.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68222 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 25.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days expressed as a fraction of total number of animals 68231 829
E3 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 0.0 % in vivo visual assessment 1.296E7 0 70130 1282
E3 subjects with ankylosis to total subjects with arthritis ratio pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 0.0 % in vivo visual assessment tail 1.296E7 0 70136 1282
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 33.0 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to38 days 69382 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 5.5 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days days 69383 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 38.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69387 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 90.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69394 892
DA/Ztm subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 38.0 % in vivo visual assessment 0.0 0 69630 1161
DA/Ztm post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 median 14.0 d in vivo visual assessment 0.0 0 69636 1161
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 33.0 % in vivo visual assessment 0.0 0 69643 1161
LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 28 50.0 % in vivo visual assessment 0.0 0 69647 1161
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 100.0 % in vivo visual assessment 0.0 0 69661 1159
LEW.1N percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 54.0 % in vivo visual assessment 0.0 0 69678 1159
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 22 82.0 % in vivo visual assessment 0.0 0 visual observation 69487 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 15.8 d 1.9 8.9 in vivo visual assessment 0.0 0 69489 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 89.0 % 33.0 in vivo visual assessment 0.0 0 visual observation 69497 837
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 60.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67873 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 81.2 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67874 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 19.7 d 2.48 8.6 in vivo visual assessment 0.0 0 69376 837
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 18 33.0 % in vivo visual assessment 0.0 0 69717 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 69.0 % in vivo visual assessment 0.0 0 69718 1162
IER/Ihr percentage of study population developing cataract during a period of time control condition Yokoyama M, et al., Mamm Genome 2001 Mar;12(3):207-11. lens clarity trait female 0 days-120 days 70 100.0 % in vivo visual assessment 0.0 0 69906 1239
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69722 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 16.0 d 0.4 1.33 in vivo visual assessment 0.0 0 69774 1162
DA/Ztm post-insult time to onset of experimental arthritis Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 14.9 d 0.5 2.0 in vivo visual assessment 0.0 0 69775 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 14.5 d 0.5 1.73 in vivo visual assessment 0.0 0 69777 1162
PVG.1AV1 post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 14.6 d 0.4 1.55 in vivo visual assessment 0.0 0 69778 1162
E3 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 5 0.0 % in vivo visual assessment 0.0 0 69816 1163
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 100.0 % in vivo visual assessment 0.0 0 69713 1162
HanTac:WH litter size bisphenol A (5 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 18 11.4 null 0.61 2.6 in vivo visual assessment 0.0 0 96600 1559
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 10 100.0 % in vivo visual assessment 0.0 0 84879 1301
HanTac:WH gestation period length bisphenol A (50 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. gestation period duration female 0 days 18 23.0 d 0.07 0.3 in vivo visual assessment 0.0 0 96586 1559
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 14.0 d 0.42 1.4 in vivo visual assessment 0.0 0 84917 1301
HanTac:WH number of fetuses lost perinatally to litter size ratio bisphenol A (0.025 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. stillborn offspring quantity female 0 days 21 10.8 % 2.71 12.4 in vivo visual assessment 0.0 0 96593 1559
HanTac:WH number of perinatal live-born offspring deaths to litter size ratio vehicle control condition (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. total life span female 0 days 18 3.2 % 1.27 5.4 in vivo visual assessment 0.0 0 96602 1559
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 100.0 % in vivo visual assessment 0.0 0 84883 1301
BDIX.BDIV-D6Mit1-D6Mgh2/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait female 200 days 49 10.0 % 0.46 3.25 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98146 2018
BDIX.BDIV-D6Mit8-D6Rat229/Zte percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait male 200 days 56 25.0 % 0.8 6.0 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98152 2018
BDIV ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 200 days 112 100.0 % in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98173 2018
LOU/M experimental autoimmune encephalomyelitis duration rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 8.0 d 0.0 0.0 in vivo visual assessment 0.0 0 110789 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 5 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110792 3186
LOU/M post-insult time to onset of experimental autoimmune encephalomyelitis Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 5 11.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110796 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (5 mg) then cyclophosphamide (8 mg) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110793 3186
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 30.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69426 892
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 81.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68225 829
DA/ZtmRhd post-insult time to onset of experimental arthritis pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 14.0 d 0.32 1.0 in vivo visual assessment 1.296E7 0 70131 1282
DA/ZtmRhd subjects with ankylosis to total subjects with arthritis ratio pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 75.0 % in vivo visual assessment tail 1.296E7 0 70134 1282
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 10.7 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days days 69381 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 50.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69384 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 20.9 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days days 69393 892
E3/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 3 0.0 % in vivo visual assessment 0.0 0 69954 1258
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 13.3 d 0.54 1.8 in vivo visual assessment 0.0 0 84922 1301
DXE1/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 10.0 % in vivo visual assessment 0.0 0 69681 1159
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 12 92.0 % in vivo visual assessment 0.0 0 68122 837
LEW/Han percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 82.0 % in vivo visual assessment 0.0 0 69660 1159
DXE1/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 70.0 % in vivo visual assessment 0.0 0 69665 1159
DA/ZtmRhd post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 17 14.0 d 0.49 2.0 in vivo visual assessment 0.0 0 69671 1159
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 14.8 d 2.4 8.3 in vivo visual assessment 0.0 0 69491 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 21 21.9 d 2.47 11.3 in vivo visual assessment 0.0 0 69494 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 15.6 d 9.4 in vivo visual assessment 0.0 0 69499 837
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 13 15.5 d 0.2 0.72 in vivo visual assessment 0.0 0 69783 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 16.4 d 0.8 2.53 in vivo visual assessment 0.0 0 69791 1162
DA/ZtmRhd post-insult time to onset of experimental arthritis pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 104 12.0 d 0.2 2.04 in vivo visual assessment 2419200.0 0 69842 1164
HanTac:WH litter size bisphenol A (50 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 18 11.2 null 0.97 4.1 in vivo visual assessment 0.0 0 96601 1559
HanTac:WH number of perinatal live-born offspring deaths to litter size ratio bisphenol A (5 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. total life span female 0 days 18 1.0 % 0.66 2.8 in vivo visual assessment 0.0 0 96605 1559
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 5 13.4 d 2.0 4.47 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68203 829
HanTac:WH gestation period length vehicle control condition (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. gestation period duration female 0 days 18 23.0 d 0.14 0.6 in vivo visual assessment 0.0 0 96583 1559
HanTac:WH gestation period length bisphenol A (5 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. gestation period duration female 0 days 18 22.9 d 0.05 0.2 in vivo visual assessment 0.0 0 96585 1559
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 14 100.0 % in vivo visual assessment 3024000.0 0 70147 1299
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 14.9 d 1.03 3.4 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68133 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 12 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68710 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 19.2 d 1.24 3.5 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68715 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68724 839
LEW/SsNHsd percentage of study population developing experimental arthritis during a period of time 0.9% sodium chloride solution (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait not specified 77 days-105 days 6 0.0 % in vivo visual assessment 0.0 0 97069 1158
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 8 100.0 % in vivo visual assessment 0.0 0 84884 1301
HanTac:WH number of perinatal live-born offspring deaths to litter size ratio bisphenol A (0.025 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. total life span female 0 days 21 3.3 % 1.57 7.2 in vivo visual assessment 0.0 0 96603 1559
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 17.0 d 0.93 2.8 in vivo visual assessment 0.0 0 84900 1301
HanTac:WH number of fetuses lost perinatally to litter size ratio bisphenol A (0.25 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. stillborn offspring quantity female 0 days 17 9.2 % 1.92 7.9 in vivo visual assessment 0.0 0 96594 1559
WF.WKY-(D7Uwm25-D7Rat128)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 43 7.2 null 0.46 3.0 in vivo visual assessment 0 DMBA oral gavage 105 days 66063 654
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67850 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67860 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 8.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68195 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68201 829
DA.ACI-(D10Rat2-D10Rat6) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 18.9 d 2.2 6.22 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68206 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 56.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68210 829
DA.F344-(D10Rat204-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 9 100.0 % in vivo visual assessment 3024000.0 0 70154 1299
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) (for 56 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 30 93.0 % in vivo visual assessment 4838400.0 0 69591 1160
LEW.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 0.0 % in vivo visual assessment 0.0 0 70189 1301
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 100.0 % in vivo visual assessment 0.0 0 70199 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 37 5.0 % in vivo visual assessment 0.0 0 70201 1301
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 13.3 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68731 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 0.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68733 829
WF.WKY-(D5Uwm78-D5Uwm98)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 32 2.8 null 0.3 1.7 in vivo visual assessment 0.0 0 70301 653
WF.WKY-(D5Uwm77-D5Uwm91)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 12 3.8 null 0.8 2.77 in vivo visual assessment 0.0 0 70313 653
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68706 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68709 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 6 21.2 d 0.53 1.3 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68711 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68714 839
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 16.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69413 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 11.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69416 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 32.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69427 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 9 5.9 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69432 892
SHR/OlaIpcv litter size control condition Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33. single birth offspring quantity male 90 days 9 7.6 null 0.73 2.2 in vivo visual assessment 0.0 0 69023 1076
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 26.5 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 37 days 69380 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 16.7 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 38 days 69391 892
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 69.0 % 48.0 in vivo visual assessment 0.0 0 visual observation 69498 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 20 60.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68124 838
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 19 10.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 DA.PVG.1AV1-(D4Got128-D4Got136) for strain 68126 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 23 100.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68128 838
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 100.0 % in vivo visual assessment 0.0 0 69624 1161
LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 13 85.0 % in vivo visual assessment 0.0 0 69627 1161
LEW.1AV1 subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 1 0.0 % in vivo visual assessment 0.0 0 69635 1161
DA/Ztm post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 median 14.0 d in vivo visual assessment 0.0 0 69637 1161
LEW.1N percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 64.0 % in vivo visual assessment 0.0 0 69662 1159
E3/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 23 9.0 % in vivo visual assessment 0.0 0 69664 1159
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 17.0 d 1.26 4.0 in vivo visual assessment 0.0 0 69669 1159
LEW.1F percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 100.0 % in vivo visual assessment 0.0 0 69677 1159
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 15.4 d 0.5 1.66 in vivo visual assessment 0.0 0 69781 1162
DA.PVG.1AV1-(D4Rat155-Spr) post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 24 12.5 d 0.5 2.45 in vivo visual assessment 0.0 0 69787 1162
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 8 100.0 % in vivo visual assessment 0.0 0 69814 1163
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 14 31.0 d 7.0 26.19 in vivo visual assessment 0.0 0 69817 1163
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 0.0 % in vivo visual assessment 0.0 0 69707 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 100.0 % in vivo visual assessment 0.0 0 69709 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69714 1162
HanTac:WH litter size vehicle control condition (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 18 11.8 null 0.78 3.3 in vivo visual assessment 0.0 0 96597 1559
HanTac:WH number of perinatal live-born offspring deaths to litter size ratio bisphenol A (50 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. total life span female 0 days 18 8.6 % 5.52 23.4 in vivo visual assessment 0.0 0 96606 1559
HanTac:WH number of male offspring to litter size ratio bisphenol A (5 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 18 49.7 % 3.61 15.3 in vivo visual assessment 0.0 0 96610 1559
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 18 14.8 d 0.75 3.2 in vivo visual assessment 0.0 0 84926 1301
HanTac:WH gestation period length bisphenol A (0.25 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. gestation period duration female 0 days 17 22.9 d 0.15 0.6 in vivo visual assessment 0.0 0 96582 1559
DA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 0.0 % in vivo visual assessment 0.0 0 84873 1301
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 100.0 % in vivo visual assessment 0.0 0 84875 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 93.0 % in vivo visual assessment 0.0 0 84469 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 16.3 d 0.94 2.3 in vivo visual assessment 0.0 0 84472 1301
HanTac:WH number of fetuses lost perinatally to litter size ratio vehicle control condition (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. stillborn offspring quantity female 0 days 18 8.5 % 1.89 8.0 in vivo visual assessment 0.0 0 96592 1559
BDIX percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait female 200 days 52 41.0 % 1.07 7.75 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98143 2018
BDIX percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait both 200 days 109 49.0 % 0.48 5.0 in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis SD approximated from 95%CI 98144 2018
BDIV percentage of study population displaying trigeminal nerve neurilemmomas at a point in time N-ethyl-N-nitrosourea (80 ug/g) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. trigeminal nerve integrity trait male 200 days 63 0.0 % in vivo visual assessment 0.0 0 inferred from Kaplan-Meier plot analysis 98155 2018
BDIX ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 200 days 57 45.0 % 0.66 5.0 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98158 2018
BDIX ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 200 days 109 51.0 % 0.48 5.0 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98160 2018
BDIX.BDIV-D6Rat132-D6Rat229/Zte ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait both 200 days 24 80.0 % 1.79 8.75 in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98167 2018
BDIV ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time N-ethyl-N-nitrosourea (80 mg/kg) van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. life span trait male 200 days 63 100.0 % in vivo visual assessment 0.0 ENU injection 200 days PI time in S1 ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) 98171 2018
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 16 0.0 % in vivo visual assessment 0.0 150 days two treatment regimen saline control group 111150 3196
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 0.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110791 3186
LOU/M experimental autoimmune encephalomyelitis duration Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 3 8.0 d 0.0 0.0 in vivo visual assessment 2592000.0 0 110802 3186
LOU/M percentage of study population developing experimental autoimmune encephalomyelitis during a period of time Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. central nervous system integrity trait not specified 95 days-114 days 4 100.0 % 0.0 0.0 in vivo visual assessment 2592000.0 0 110795 3186
WF mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. mammary gland integrity trait female 155 days-160 days 19 7.3 null 0.83 3.6 in vivo visual assessment 0 DMBA oral gavage 105 days 66067 654
LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 17 median 24.0 d in vivo visual assessment 0.0 0 69648 1161
DA/ZtmRhd percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 17 100.0 % in vivo visual assessment 0.0 0 69663 1159
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 17 25.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69424 892
DA/ZtmRhd arthritic paw count pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 3.7 null 0.16 0.5 in vivo visual assessment tail 1.296E7 0 70137 1282
E3 arthritic paw count pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 10 0.0 null in vivo visual assessment tail 1.296E7 0 70139 1282
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 33.9 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69388 892
DA/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 17 100.0 % in vivo visual assessment 0.0 0 69679 1159
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 14 86.0 % in vivo visual assessment 0.0 0 69813 1163
E3 percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 5 0.0 % in vivo visual assessment 0.0 0 69815 1163
DA/ZtmRhd arthritic paw count pristane (150 ul) Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16. joint integrity trait both 56 days-84 days 104 3.3 null 0.1 1.02 in vivo visual assessment 2419200.0 0 69840 1164
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 73.0 % in vivo visual assessment 0.0 0 69705 1162
DXE3/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) (for 110 days) Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32. joint integrity trait both 0 days 29 3.0 % in vivo visual assessment 9504000.0 0 70142 1298
DA.F344-(D10Arb20-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70152 1299
HanTac:WH areola mammae/nipple number bisphenol A (0.025 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. nipple quantity male 14 days 17 0.2 null 0.07 0.3 in vivo visual assessment 0.0 0 96628 1559
HanTac:WH litter size bisphenol A (0.25 mg/kg/d) (for 14 days) Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014. single birth offspring quantity female 0 days 17 12.1 null 0.85 3.5 in vivo visual assessment 0.0 0 96599 1559
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 3 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68721 839
WF.WKY-(D5Uwm95-D5Uwm98)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 36 7.4 null 0.6 3.6 in vivo visual assessment 0.0 0 70302 653
WF.WKY-(D5Uwm88-D5Uwm92)/Uwm mammary tumor number 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. mammary gland integrity trait female 155 days-160 days 58 6.9 null 0.6 4.57 in vivo visual assessment 0.0 0 70308 653
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 16 68.8 % in vivo visual assessment 0.0 0 84872 1301